Marieke van Son

158 CHAPTER 8 12. Bomers JGR, Overduin CG, Jenniskens SFM, Cornel EB, van Lin ENJT, Sedelaar JPM, et al. Focal Salvage MR Imag- ing–Guided Cryoablation for Localized Prostate Cancer Recurrence after Ra- diotherapy: 12-Month Follow-up. J Vasc Interv Radiol 2020;31:35–41. https://doi. org/10.1016/j.jvir.2019.07.001. 13. Duijzentkunst DAS, Peters M, van der Voort van Zyp JRN, Moerland MA, van Vulpen M. Focal salvage therapy for local prostate cancer recurrences after prima- ry radiotherapy: a comprehensive review. World J Urol 2016;34:1521–31. https:// doi.org/10.1007/s00345-016-1811-9. 14. Henríquez I, Sancho G, Hervás A, Guix B, Pera J, Gutierrez C, et al. Salvage brachytherapy in prostate local re- currence after radiation therapy: Pre- dicting factors for control and toxicity. Radiat Oncol 2014;9:1–8. https://doi. org/10.1186/1748-717X-9-102. 15. Peters M, Kanthabalan A, Shah TT, McCartan N, Moore CM, Arya M, et al. Development and internal validation of prediction models for biochemical fail- ure and composite failure after focal sal- vage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient progn. Urol Oncol Semin Orig In- vestig 2018;36:13.e1-13.e10. https://doi. org/10.1016/j.urolonc.2017.08.022. 16. Peters M, van der Voort van Zyp JRN, Moerland MA, Hoekstra CJ, van de Pol S, Westendorp H, et al. Development and internal validation of a multivari- able prediction model for biochemi- cal failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer. Brachyther- apy 2016;15:296–305. https://doi. org/10.1016/J.BRACHY.2016.01.004. 17. Maenhout M, Peters M, van Vulpen M, Moerland MA, Meijer RP, van den Bosch MAAJ, et al. Focal MRI-Guided Salvage High-Dose-Rate Brachyther- apy in Patients With Radiorecurrent Prostate Cancer. Technol Cancer Res Treat 2017;16:1194–201. https://doi. org/10.1177/1533034617741797. 18. Grignon DJ, Sakr WA. Histolog- ic effects of radiation therapy and total androgen blockade on pros- tate cancer. Cancer 1995;75:1837– 41. https://doi.org/10.1002/1097- 0142(19950401)75:7+<1837::AID-CN- CR2820751613 >3.0.CO; 2-S. 19. Crook JM, Bahadur YA, Robertson SJ, Perry GA, Esche BA. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 1997;79:81–9. https:// doi.org/10.1002/ (SICI)1097-0142(1997 0101)79:1<81::AID-CNCR12 >3.0.CO ;2-2. 20. Goldstein NS, Martinez A, Vicini F, Stromberg J. The histology of radiation therapy effect on prostate adenocar- cinoma as assessed by needle biopsy after brachytherapy boost: Correlation with biochemical failure. Am J Clin Pathol 1998;110:765–75. https://doi. org/10.1093/ajcp/110.6.765. 21. Riley RD, Ensor J, Snell KIE, Harrell FE, Martin GP, Reitsma JB, et al. Calculat- ing the sample size required for devel- oping a clinical prediction model. BMJ 2020;368:1–12. https://doi.org/10.1136/ bmj.m441. 22. White IR, Royston P. Imputing missing covariate values for the Cox model. Stastics Med 2009;28:1982–1998. https://doi.org/1. 23. Moons KGM, Donders RART, Sti- jnen T, Harrell FE. Using the outcome for imputation of missing predictor values was preferred. J Clin Epide- miol 2006;59:1092–101. https://doi. org/10.1016/j.jclinepi.2006.01.009.